Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00400634
Other study ID # CERE-120-02
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 2006
Est. completion date November 2008

Study information

Verified date August 2019
Source Sangamo Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease. CERE-120 is administered via bilateral stereotactic injections targeting the putaminal region of the brain. The design of this study involves approximately 34 patients receiving CERE-120 treatment via stereotactic surgery and approximately 17 patients receiving sham stereotactic surgery (no CERE-120 administered).


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date November 2008
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender All
Age group 35 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of bilateral, idiopathic Parkinson's Disease (PD) based on UK Brain Bank criteria with motor complications despite adequate oral antiparkinsonian therapy. - At least 5 years disease duration, relative to the anticipated date of surgery, since diagnosis of PD. - Males or nonpregnant females 35-75 years of age, inclusive. - A UPDRS motor scale score of 30 or greater in the practically defined off condition during the 30-day eligibility evaluation period. - Stable doses of antiparkinsonian medications and parkinsonian features for the 60-day period preceding the surgical procedure. - No conditions that would render the subject unsuitable for surgery, or that would interfere with any of the assessments of efficacy or safety in this trial. - Subject's informed consent prior to the performance of any study-specific procedures. Exclusion Criteria: - Subjects with atypical or secondary parkinsonism. - Any subject, in the judgment of the investigator, for whom participation in the study would pose a safety risk including, but not limited to, a history of any clinically significant medical, psychiatric, or laboratory abnormality. - History of treatment of PD by any procedure involving intracranial surgery or implantation of a device. - MRI of the brain within 12 months before the surgical procedure that indicates the presence of an abnormality that may interfere with the assessments of safety or efficacy or would, in the judgment of the investigator, represent a surgical risk to the subject. - Any disorder that precludes a surgical procedure (e.g., signs of sepsis or inadequately treated infection) or alters wound healing. - Receipt of antiplatelet agents for at least 10 days prior to the surgical procedure. - A score of less than or equal to 27 on the Folstein Mini-Mental examination performed during the eligibility evaluation period or clinical evidence of cognitive impairment that would affect the subject's ability to sign the informed consent or perform any of the protocol required assessments. - Chemotherapy, cytotoxic therapy, or immunotherapy within 6 weeks prior to the surgical procedure. - Vaccinations within 30 days prior to the surgical procedure. - History, within 2 years before the surgical procedure, of drug or alcohol abuse. - Treatment with neuroleptics within 1 year before the surgical procedure. - Any medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of efficacy and safety in this trial or would compromise the ability of the subject to undergo study procedures (e.g., MRI, PET), or give informed consent. - History of prior gene transfer therapy. - Treatment with an investigational agent within 60 days before the surgical procedure.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
CERE-120 5.4 x 10^11 vg
Procedure:
Sham Surgery
Bilateral partial thickness burr holes placed, no intraparenchymal injections

Locations

Country Name City State
United States University of Alabama, Birmingham Birmingham Alabama
United States Rush University Medical Center Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States Duke University Medical Center Durham North Carolina
United States Baylor College of Medicine Houston Texas
United States Mount Sinai School of Medicine New York New York
United States Pennsylvania Hospital Philadelphia Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States University of California, San Francisco San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
Sangamo Therapeutics Ceregene

Country where clinical trial is conducted

United States, 

References & Publications (1)

Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Ko — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other UPDRS Part III OFF The UPDRS (Unified Parkinson's Disease Rating Scale) is a clinical rating scale that assesses the symptomatic burden of Parkinson's Disease. The scale has four main sections, and each item is scored from a 0 to a 4 (higher number is more severe manifestation). Part III is a subsection devoted to motor function, has 14 questions, resulting in a score range of 0 (unaffected) to 56 (severely affected). The scale is administered by a trained clinician, and patients were assessed in a practically defined "off" condition, 12 hours or more after the last administration of medication. Change from Baseline to 18 Month Visit
Primary UPDRS Part III OFF The UPDRS (Unified Parkinson's Disease Rating Scale) is a clinical rating scale that assesses the symptomatic burden of Parkinson's Disease. The scale has four main sections, and each item is scored from a 0 to a 4 (higher number is more severe manifestation). Part III is a subsection devoted to motor function, has 14 questions, resulting in a score range of 0 (unaffected) to 56 (severely affected). The scale is administered by a trained clinician, and patients were assessed in a practically defined "off" condition, 12 hours or more after the last administration of medication. Change from Baseline to 12 Month Visit
See also
  Status Clinical Trial Phase
Completed NCT03665493 - Dopamine Effect on Inhibitory Control N/A
Completed NCT02227355 - Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease N/A
Completed NCT01026428 - A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Phase 1/Phase 2
Completed NCT00664157 - Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus N/A
Completed NCT04524143 - The Acute Effect of Cervical Mobilization in Parkinson's Disease N/A
Completed NCT05107531 - Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
Completed NCT04524182 - The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease N/A
Completed NCT00985517 - Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT01968031 - A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Phase 3
Completed NCT01970813 - Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease N/A
Completed NCT01221948 - Vercise Implantable Stimulator for Treating Parkinson's Disease Phase 2
Terminated NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) Phase 3
Completed NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT02240030 - Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Phase 3
Completed NCT00605683 - MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Phase 3
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Completed NCT02565628 - PF-06669571 In Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT01617135 - Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Phase 2
Completed NCT01606670 - Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
Terminated NCT00261781 - Walking Capacity in Parkinson's Disease (PD-Walk) N/A